Figure 1.

Overview of the integrative workflow used to investigate CHID1 in GBM. This schematic illustrates the overall study design integrating computational multi-omics analyses with experimental validation to characterize the role of CHID1 in GBM. Public transcriptomic datasets from TCGA-GBM and CGGA were analyzed to evaluate CHID1 differential expression, prognostic significance, and immune infiltration using platforms including GEPIA2, UALCAN, and TIMER2.0. Protein-protein interaction networks, DNA methylation patterns, and functional enrichment analyses were examined through STRING, MethSurv, Gene Ontology (GO), KEGG pathway analysis, GSEA, and MetaCore. Pharmacogenomic associations and molecular docking analyses were further performed to explore potential therapeutic relevance. Finally, protein-level validation of CHID1 expression was conducted using immunohistochemical staining of clinical brain tumor tissue microarrays.